Portal de Periódicos da CAPES

Quad's in it for antiretroviral therapy?

2012; Elsevier BV; Volume: 379; Issue: 9835 Linguagem: Inglês

10.1016/s0140-6736(12)61029-0

1474-547X

Rik Schrijvers, Zeger Debyser,

HIV Research and Treatment

In The Lancet, the GS-US-236-0102 1 Sax PE DeJesus E Mills A et al. for the GS-US-236-0102 study teamCo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379: 2439-2448 Summary Full Text Full Text PDF PubMed Scopus (380) Google Scholar and GS-236-0103 2 DeJesus E Rockstroh JK Henry K et al. for the GS-236-0103 study teamCo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379: 2429-2438 Summary Full Text Full Text PDF PubMed Scopus (320) Google Scholar study teams assessed the efficacy and safety of the latest single-tablet regimen—combining elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)—against HIV-1 infection. Antiretroviral therapy has undergone substantial development. In addition to efficacy, tolerability, including the short-term and long-term side-effects combined with the convenience of a regimen, is a very important index to guide therapeutic choices. 26 antiretroviral drugs from six different classes are now approved, which has enabled individualised treatment in many patients. Furthermore, tremendous progress has been made in downscaling the pill burden of combination regimens, thus improving adherence, 3 Airoldi M Zaccarelli M Bisi L et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010; 4: 115-125 PubMed Google Scholar a cornerstone in the treatment of HIV/AIDS. Treatment can often be given once daily with a single-tablet regimen as the simplest option. Therefore, new drugs should have at least equal efficacy (assessed in non-inferiority trials) and preferably an advantage over established regimens in their tolerability profile. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialIf regulatory approval is given, EVG/COBI/FTC/TDF would be the first integrase-inhibitor-based regimen given once daily and the only one formulated as a single tablet for initial HIV treatment. Full-Text PDF Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksIf regulatory approval is given, EVG/COBI/FTC/TDF would be the only single-tablet, once-daily, integrase-inhibitor-based regimen for initial treatment of HIV infection. Full-Text PDF